Chemical Nametucatinib
Dosage FormTablets (oral; 50 mg, 150 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
CompanySeattle Genetics, Inc.
Approval Year2020


  • Indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tukysa (tucatinib) Prescribing Information.2020Seattle Genetics, Inc., Bothell, WA